Microbix Biosystems Inc. · TSX:MBX

Microbix Biosystems — Shareholder Meeting (March 2021)

20 slides from Microbix Biosystems's shareholder meeting presentation, March 2021

  1. Slide 1: AGM Presentation March 2021

    BIOSYSTEMS INC. Infectious Disease Specialists AGM Presentation March 2021

  2. Slide 2: Welcome & Forward-Looking Statements

    Welcome & Forward-Looking Statements • Welcome to Microbix’s Annual General Meeting of 2021. • We deeply appreciate your interest and support. • Shareholder questions will be answered following this presentation. • Note that this management presentation contains forward-looking statements about tren

  3. Slide 3: Board of Directors

    Board of Directors Martin Marino Mr. Marino has more than 30 years’ experience in corporate legal roles and executive Chairman management functions, with emphasis on transaction-based corporate development. He also has considerable experience in conflict resolution and litigation management. Dr. Pet

  4. Slide 4: Senior Management (Our Top 6)

    Senior Management (Our Top 6) Cameron L. Groome Has served on the MBX BoD and AC since 2012, and was appointed CEO in 2017. CEO, President, and Director 30 years’ experience in senior life sciences and finance roles. Successful leader, executive, director, and advisor for public and private companie

  5. Slide 5: Some Unsung Heroes (Other Senior Managers)

    Some Unsung Heroes (Other Senior Managers) Amer Alagic, Ph.D., MBA 14 years with Microbix. Responsible for new product and process development, including Director, R&D development & implementation of bioreactor antigen production, new QAPs, and VTM. Reports to Mark Luscher Steve Hagerman 27 years wi

  6. Slide 6: Our Company Today

    BIOSYSTEMS INC. Our Company Today Develops, makes, and sells biological products or technologies to customers in North America, Europe, Asia, and other markets. Leads in supplying native “antigens”, as a critical part of medically important infectious disease tests. This segment has averaged $1M/mon

  7. Slide 7: Microbix's Three Sales-Driven Business Divisions

    Microbix’s Three Sales-Driven Business Divisions Current platform and capacity enables accelerating sales growth by a well-established multi-product life sciences business 1 Global leader in native antigen 2 Global leader in EQA/PT controls, OEM and Lab 3 Viral Transport Media for Pandemic Testing p

  8. Slide 8: Microbix and the Pandemic

    Microbix and the Pandemic ! Our Company’s Contributions Development Timeline for • Microbix was quick to recognize an emerging global pandemic COVID-19 QAPs and VTM • Within weeks, created and validated COVID PCR-test Controls • Secured QAPs market access via regulators in Canada, EU, & US • Created

  9. Slide 9: Microbix and the Pandemic

    Microbix and the Pandemic ! Our Company’s Contributions Development Timeline for • Followed up PCR QAPs with created of antigen-test QAPs COVID-19 QAPs and VTM • Executed VTM grant funding agreement with Ontario • Strategic alliance with Copan for swab-formatted QAPs • Created VTM formula and commer

  10. Slide 10: Growth Outlook for Antigens Business

    Growth Outlook for Antigens Business 1 Antigens Antigens comprise ~70% of ✓ As healthcare re-stabilizes, may benefit from greater global total sales (Q1 #s), and have attention to respiratory and infectious disease testing demonstrated material sales resulting from the COVID-19 pandemic. growth over

  11. Slide 11: Our QAPs Segments and their Markets

    2 Quality Assessment Products Our QAPs Segments and their Markets ~$2.0 million in sales targeted – US$10-US$20/unit, all direct Usually unbranded (White Label) • Sold directly to a limited pool of lab accreditation organizations • Targeted to double from its current base of ~$1.0M/year >$10 million

  12. Slide 12: PT was just the start for QAPs

    PT was just the start for QAPs™ 2 Quality Assessment Products Microbix is now opening new markets, providing its QAPs to key participants across the diagnostics industry. PROCEEDx™ – For REDx Controls™ – To qualifying new support the formal QC instruments and and QA programs of training technicians

  13. Slide 13: Viral Transport Medium (VTM) for Ontario

    Viral Transport Medium (VTM) 3 VTM for Ontario → Why this Project? Specific Microbix Activities: Expertise in large-scale biological media Identified Need of Ontario production enables Microbix to provide Ontario Outreach to MEDJCT with a secure local supply of high-quality VTM. Security of supply b

  14. Slide 14: Sales Potential for VTM

    Viral Transport Medium (VTM) 3 VTM for Ontario → Sales Potential for VTM Every PCR test conducted by Ontario requires a vial of VTM – Currently at 40-60,000 tests per day, with needs expected to increase, to support restart of travel, schools, enterprises, etc. • Microbix has started initial product

  15. Slide 15: Kinlytic Urokinase Partnering Opportunity

    Partnering Opportunity 4 Kinlytic® Urokinase → Kinlytic® Urokinase Urokinase is a human protein that dissolves blood clots and has been used to treat multiple clot-related disorders in millions of patients. • The U.S. return of Kinlytic starts with its FDA-approved use for catheter clearance. • Clea

  16. Slide 16: FY 2020 Results & FY 2021 Targets

    FY 2020 Results & FY 2021 Targets 5 Financials COVID-19 changed sales for antigens & QAPs, while creating its own opportunities. • Of all infectious disease testing, only that for COVID-19 has increased during the pandemic. • Microbix has created & launched leading COVID-19 products with its new QAP

  17. Slide 17: Microbix's Opportunities

    Microbix’s Opportunities Actions ✓ Continue Sales & Margin Growth for antigens ✓ Register/Launch New Products in QAPs TM lines ✓ Deliver as Key Supplier of VTM for Ontario & more ✓ Enhance Gross Margins across all products ✓ Drive Cash Flow from operations Results ✓ Repositioned as an Innovative Med

  18. Slide 18: Capital Structure

    Capital Structure 0.7 3000000 0.6 2500000 0.5 2000000 0.4 1500000 0.3 1000000 0.2 0.1 500000 0 0 23-Apr-20 23-May-20 23-Jun-20 23-Aug-20 23-Nov-20 23-Dec-20 23-Jan-21 23-Mar-20 23-Sep-20 23-Oct-20 23-Feb-21 23-Mar-21 23-Jul-20 TSX Listed, Symbol: MBX • OTC QB Listed, Symbol: MBXBF Current Price $0.5

  19. Slide 19: Takeaway Messages

    Takeaway Messages A Real Business – Growing sales to a broad range of local & int’l customers Big Opportunities – Realizable potential from in-scope operations and projects • Growing sales of antigens at improving margins • New offerings and customers for QAPs™ • Emerging opportunity for large-scale

  20. Slide 20: Thank You

    20 THANK YOU Cameron Groome BIOSYSTEMS INC. CEO, President, and Director cameron.groome@microbix.com

Microbix Biosystems — Shareholder Meeting (March 2021) on 6ix